Dr David Spigel reviews 3 of the most important, practice-changing topics at ASCO 2018: new therapies targeting RET in a number of tumor types, a prognostic biomarker assay to predict whether patients with breast cancer will need adjuvant hormonal therapy or chemotherapy, and the minimum level of PD-L1 positivity required to predict outcomes with immunotherapy in lung cancer.
Related Items
Web Exclusives published on December 9, 2021 in ASCO, Biliary Tract Cancer, Cholangiocarcinoma, Pancreatic Cancer
2020 Year in Review - Lung Cancer published on January 20, 2021 in Lung Cancer
2020 Year in Review - Lung Cancer published on January 20, 2021 in Lung Cancer
Last modified: July 22, 2021
